By clicking "Allow," you will be taken to a website that is independent of ViiV Healthcare. The site you linking to is not controlled or endorsed by ViiV Healthcare, and ViiV Healthcare is not responsible for the content provided on that site.
This site is exclusively for healthcare professionals in the US. It contains medical information about ViiV Healthcare medications.
It may include information about products or uses that have not been approved by the US Food and Drug Administration.
If you are not a healthcare provider, discuss any questions you have regarding your health or medicines with your doctor, pharmacist, or nurse.
Real‐world utilization of cabotegravir/rilpivirine: an observational analysis of adherence and persistence using a patient support programme in Canada, preliminary results
Similar virological outcomes and frequency of isolated viraemic events (blips, low‐level viraemia and suspected virological failure) between oral and long‐acting antiretroviral therapy: a pooled analysis of phase III/IIIb cabotegravir + rilpivirine long‐acting studies
Two‐year long‐term data on the efficacy and tolerability of dolutegravir‐based regimens from the prospective multi‐centre TESLA cohort study in ART‐naïve and pre‐treated people living with HIV in Russia
Treatment‐emergent integrase strand transfer inhibitor (INSTI) resistance‐associated mutations among people living with HIV‐1 treated with dolutegravir (DTG) + lamivudine (3TC) with pre‐existing M184V/I from real‐world and interventional studies
A multicentre observational study to determine the safety and effectiveness of dolutegravir (DTG) use during pregnancy: data from DOLOMITE‐NEAT ID Network study
CARAVEL: evaluation of real‐world effectiveness and sustainability of the two‐drug regimen dolutegravir/lamivudine fixed‐dose combination in treatment‐naive adults and pre‐treated adults who are virologically suppressed, in routine clinical care, in France: 2‐year interim analysis results
PAIRED ‐PAtIent Reported Experiences and perceiveD benefit of treatment with dolutegravir/lamivudine (DTG/3TC): a sub‐analysis of people with HIV (PWH) switching from bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in the United States
Similar efficacy, safety and CD4 T‐cell increase up to week 96 observed with fostemsavir (FTR)‐based regimens in the BRIGHTE study and dolutegravir (DTG)‐based regimens in the VIKING‐3 study in individuals with multidrug‐resistant (MDR) HIV‐1
CD4 T‐cell, CD4/CD8 ratio improvement and a general reduction in inflammatory biomarkers with lowlevel viraemia (LLV) up to week 192 with fostemsavir (FTR)‐based regimens in individuals with multidrug‐resistant (MDR) HIV‐1
VH3810109 (N6LS) administration dose‐responsively enhances anti‐HIV antibody‐dependent cellular cytotoxicity (ADCC) and antibody‐dependent cellular phagocytosis (ADCP) activity in ex vivo models
Differences in oral PrEP use patterns and intention to use long-acting regimens among MSM between formal and informal PrEP provision pathways in 20 European countries: a latent class analysis
Preparing for long‐acting PrEP delivery: provider preferences for the provision of long‐acting PrEP differ between MSM and heterosexual individuals in Europe
Feasibility and satisfaction of interventions measures (FIM and HIVTISQ) of implementation long‐acting (LA) CAB+RPV administration out of HIV units: the IMADART study
Re‐suppression regimens and outcomes after virological failure in randomized controlled trials and real‐world evidence studies evaluating cabotegravir and rilpivirine (CAB+RPV)
Cabotegravir and rilpivirine concentrations and HIV-1 RNA suppression in male and female genital fluids and rectal tissue in people with HIV on antiretroviral therapy with long-acting intramuscular cabotegravir plus rilpivirine
Use of long‐acting cabotegravir and rilpivirine in a real‐life setting: 12‐month results of virological outcome, adherence, safety, durability, in the ANRS CO3 AquiVIH‐NA Cohort‐France
Abstract available on HIV Glasgow website
Hidalgo‐Tenorio C, et al.
Results at month 7 of CABO‐CHANCE study: real‐world evidence (RWE) on the use of intramuscular cabotegravir plus rilpivirine long‐acting (CAB+RPV LA) dosed every 2 months in viral suppressed people with HIV (PWH)
Virological failure rate and emergent resistance in real‐world studies evaluating long‐acting cabotegravir and rilpivirine in people with baseline viral suppression
Efficacy of dolutegravir plus lamivudine in treatment‐naïve people living with HIV without baseline drug‐resistance testing available: 48‐week results from the randomised D2ARLING study
Long‐term efficacy and safety of dolutegravir/lamivudine in virologically suppressed persons with HIV and history of resistance to lamivudine: week 96 results of VOLVER clinical trial ‐ GESIDA 11820
Comparable efficacy and safety of dolutegravir/lamivudine to a three drug regimen amongst ARV naive people living with HIV with CD4 <200/mm3: the DOLCE study
Changes in patient‐reported neuropsychological outcomes in virologically suppressed persons with HIV switching to DTG/3TC or BIC/FTC/TAF: a substudy of the PASO‐DOBLE randomized clinical trial
Efficacy and safety of dolutegravir (DTG)‐based antiretroviral treatment (ART) in patients with HIV and solid organ transplantation (SOT): a single‐arm clinical trial (DTG‐SOT)
Abstract available on HIV Glasgow website
Ryan R, et al.
Dolutegravir‐based antiretroviral therapy does not reduce plasma levonorgestrel or medroxyprogesterone acetate concentrations among contraceptive users living with HIV compared with HIV‐negative controls
Comparison of four frailty scores to predict adverse health outcomes and mortality in people living with HIV aged 70 years and more (ANRS EP66 SEPTAVIH study)
Abstract available on HIV Glasgow website
Deb S, et al.
The association between anticholinergic medication use and cognitive function in older people with HIV in the Pharmacokinetic and clinical Observations in PeoPle over fiftY (POPPY) study
Abstract available on HIV Glasgow website
Sukumaran L, et al.
The prevalence and factors associated with polypharmacy in participants with HIV in the Pharmacokinetic and clinical Observations in PeoPle over fiftY (POPPY) study over a 3‐5 year period
Kelli is available in the Ohio area. If this is not your area, enter a zip code to find your MSL contact
This site uses cookies and similar technologies (collectively, "cookies") to enhance your website experience and track the site's performance. These cookies are automatically enabled. By using this site, you agree to our use of these cookies in accordance with our Privacy Notice. Click on Privacy Choices below to manage your preferences, including to opt out of the sale or sharing of your information.
Managing Privacy Options
OPT OUT OF SALE AND SHARING OF INFORMATION
Your state law may allow you the right to opt out of the sale or sharing of your personal information for targeted advertising. You may opt out of such sale or share via the toggle available to you for "Targeting Cookies," and selecting the "Confirm my choices” button below. To limit sale or sharing of your information for targeting advertising offline, please see the "Cookies and Targeted Advertising Choices," section in the Privacy Notice and submit the required form.
Always Active
Necessary for the website to function appropriately, such as to store session data during a website visit, to manage cookie and tag preferences, and to protect the security of the website. In addition, some of these cookies are set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in, or filling in forms.
Always Active
Enable the website to provide enhanced functionality and personalization, such as by helping us to measure how many visitors come to our websites, what sites our website visitors come from, and how often certain pages on our website are viewed. These cookies may be set by us or by third party providers, like our analytics service providers, whose services we have added to our pages.
Allow us to target and re-target you with relevant advertising. We and our advertising partners use information collected through these technologies to infer your interests in order to serve you more relevant advertisements on other sites. If you don’t allow these cookies, you will receive advertising, but it may be less relevant to you.
